Cooper Companies Inc (COO) reported quarterly earnings results on Thursday, Sep-1-2016. The company said it had a profit of $2.30 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $2.29. The company posted revenue of $514.70 million in the period, compared to analysts expectations of $512.63 million. The company’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.97 EPS.
Many Wall Street Analysts have commented on Cooper Companies Inc. Company shares were Reiterated by Stifel on Aug 31, 2016 to “Buy”, Firm has raised the Price Target to $ 215 from a previous price target of $195 .Company shares were Reiterated by Stifel on Jun 30, 2016 to “Buy”, Firm has raised the Price Target to $ 195 from a previous price target of $180 .
Cooper Companies Inc opened for trading at $184.29 and hit $186.84 on the upside on Monday, eventually ending the session at $186.56, with a gain of 1.44% or 2.64 points. The heightened volatility saw the trading volume jump to 3,71,853 shares. Company has a market cap of $9,039 M.
In a different news, on Jul 12, 2016, Michael Kalkstein (director) sold 1,000 shares at $178.55 per share price. According to the SEC, on Jun 29, 2016, Stanley Md Zinberg (director) sold 10,000 shares at $170.00 per share price. On Jun 29, 2016, Randal Golden (VP, General Counsel) sold 2,000 shares at $167.31 per share price, according to the Form-4 filing with the securities and exchange commission.
The Cooper Companies Inc. (Cooper) is a global medical device company. The Company operates through two business units CooperVision Inc. (CVI) and CooperSurgical Inc. (CSI). CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying women’s health clinicians with products and treatment options to improve the delivery of healthcare to women. CooperSurgical products fall into three main segments based on the point of healthcare delivery: Hospital Office and Fertility Clinic. CooperVision develops manufactures and markets a range of monthly two-week and single-use contact lenses featuring advanced materials and optics. CooperVision is involved in correcting vision problems such as astigmatism presbyopia and ocular dryness and provides innovative contact lens solutions. The CooperVision Companys brands include Biofinity Avaira and MyDay and CooperSurgical Companys brands include Advincula Arch SeeClear and Mobius.